For research use only. Not for therapeutic Use.
Landogrozumab（Cat No.:I042223）is a monoclonal antibody designed to target and inhibit the activity of the protein myostatin, a negative regulator of muscle growth. By blocking myostatin, Landogrozumab aims to promote muscle growth and regeneration, making it a potential treatment for conditions characterized by muscle wasting, such as muscular dystrophy, sarcopenia, and cachexia. Research has shown that inhibiting myostatin can enhance muscle mass and strength. Ongoing clinical trials are evaluating the safety, efficacy, and potential therapeutic benefits of Landogrozumab in improving muscle function and treating various muscle-related diseases.
| Catalog Number | I042223 |
| CAS Number | 1391726-30-9 |
| Purity | ≥95% |
